Skip to content

Monopar Therapeutics MNPR Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$14.98M+9.6%-$13.72M+12.0%-$19.44M-200%-$17.31M-143%-$16.57M-118%
$5.18M+139%$4.84M+324%$4.01M+200%$3.11M+93.1%$2.17M+23.8%
-$10.01M+3.8%-$12.2M-90.5%-$10.83M-82.0%-$9.81M-43.9%-$10.41M-43.8%
-$68.71M-402%-$63.45M-343%-$15.6M-625%-$12.49M-729%-$13.68M-377%
$91.87M$91.96M$148.1M
$121.66M$33.38M$31.9M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monopar Therapeutics generate?
Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
Where does Monopar Therapeutics's cash flow data come from?
Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.